Pre-Clinical Research
The overall goal of Dr. Klement's research is the development of novel, non-toxic therapies for benign and malignant tumors and to improve the existing standards in cancer care. The underlying concepts of her work are easily applied to many other angiogenesis related disorders, and should help in addressing a number of areas of urgent medical needs such as:
- the development of non-toxic therapies for leukemias;
- prevention of morbidities in patients with benign soft tissue growthsthe development biomarkers for early diagnosis of cancer or cancer recurrence; and
- improving the healing in burns and chronic ulcers.
The development of non-toxic anti-cancer strategies has been the focus of Dr. Klement’s work since the early introduction of metronomic therapy in 2000 and builds on her work with Dr. Kerbel at University of Toronto. The development of early biomarkers of cancer growth and recurrence has been the focus of recent publications of Dr. Klement's research team and builds on her work that began while she was a member of Dr. Folkman's team at Harvard.